IMDX:NASDAQInsight Molecular Diagnostics Inc. analysis
Data as of Oct 1, 2026 - not real-time
- Latest price
- $3.50
- Risk: high
- 9/10High risk
Summary
Insight Molecular Diagnostics Inc. is priced at $3.50 and its moving averages line up in bearish order, the shorter trailing the longer. Across the trailing 30 sessions it lost 20.1%. Momentum indicators put RSI at 40.6 (neutral) with MACD reading bearish. Price has been bracketed by support at $3.07 and resistance at $4.32.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Consensus targets land 135.7% above where the shares trade now. Revenue is contracting at 53.9%.
On a 1-10 scale the risk profile lands at 9 — high. With 30-day volatility of 91.2%, a beta of 2.66 and a maximum drawdown of 69.9%, position sizing matters more than entry timing here. Thin trading volumes mean execution costs can be material on larger orders. The wider market backdrop reads extreme greed at 90 on the fear-greed composite.
This one splits by horizon — sell in the near term, hold further out, at 2/10 long-term conviction.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Consensus targets land 135.7% above where the shares trade now. Revenue is contracting at 53.9%.
On a 1-10 scale the risk profile lands at 9 — high. With 30-day volatility of 91.2%, a beta of 2.66 and a maximum drawdown of 69.9%, position sizing matters more than entry timing here. Thin trading volumes mean execution costs can be material on larger orders. The wider market backdrop reads extreme greed at 90 on the fear-greed composite.
This one splits by horizon — sell in the near term, hold further out, at 2/10 long-term conviction.
Top market events
- FDA review nears completion as reimbursement rates support commercial launch.
- FDA review nears completion as reimbursement rates support commercial launch.
- NASHVILLE, Tenn. AP — NASHVILLE, Tenn. AP — Insight Molecular Diagnostics Inc. IMDX on Monday reported a loss of...
Market outlook
Short term
< 1 yearCautious
Model confidence4/104 out of 10
Key factors
- Short-term moving averages stacked below long-term ones
- Trading below the 200-day average of 5.08
- MACD momentum is negative
Medium term
1–3 yearsNeutral
Model confidence3/103 out of 10
Key factors
- Short-term moving averages stacked below long-term ones
- Trading below the 200-day average of 5.08
- Analyst targets imply +135.7% versus the current price
Long term
> 3 yearsNeutral
Model confidence2/102 out of 10
Key factors
- Analyst targets imply +135.7% versus the current price
- Revenue contracting at -53.9%
- Negative free cash flow
Key metrics
Financial health
Revenue Growth-53.90%
P/E Ratio-4.4
ROA-57.82%
P/B Ratio-5.4
Op. Cash Flow$-27078000
Free Cash Flow$-18789500
Industry P/E29.9
Technical analysis
TrendBearish
RSI40.6
Support$3.07
Resistance$4.32
MA 20$3.90
MA 50$4.24
MA 200$5.08
MACDBearish
VolumeIncreasing
Fear & Greed Index90.45
Valuation
Target Price$8.25
Upside/Downside135.71%
GradeFair
TypeBlend
Risk assessment
Beta2.66
Volatility91.20%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskHigh
Similar tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.